Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023

Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023

Introduction and Objectives: Advanced liver fibrosis (ALF) is a predictor of adverse prognosis in chronic liver disease. In addition to etiological treatment, a new approach to stop or reverse residual fibrosis would be desirable. Our aim was to assess the efficacy and safety of a prolonged-release...

Full description

Bibliographic Details
Main Authors: Linda E. Munoz-Espinosa, Aldo Torre, Laura Cisneros, Iaarah Montalvo-Gordon, René Malé-Velázquez, Scherezada Mejía, Juan Ramón Aguilar-Ramírez, Javier Lizardi-Cervera, María E. Icaza-Chávez, Frida Gasca-Díaz, Larissa Hernández-Hernández, Paula Cordero-Perez, Luis A. Chi-Cervera, Lilian Torres-Made, Fátima Rodríguez-Álvarez, Graciela Tapia, Jorge Luis Poo
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268124002667

Internet

http://www.sciencedirect.com/science/article/pii/S1665268124002667

Similar Items